CELLINK has been granted a patent for a method for printing tissue constructions with a 3D printer. Patent protection applies to the Swedish market, the company also conducts the process of expanding patent protection in additional countries.
The patent protection from the Swedish Patent and Registration Office shows uniqueness and height of innovation. The patent includes a method that enables advanced calibration and printing of designs with high demands on precision and reproducibility.
“We are pleased to have this patent granted, which is proof that we work strongly with innovative technologies and to protect our products and our technologies. This helps us build a long-term business with the right focus and value for customers and shareholders. ”- Erik Gatenholm, CEO
The granted patent strengthens the company's protection for intellectual properties and is in line with the company's strategy. The company is in a phase where great focus is on the development of innovative solutions to enable printing of various tissues and organs.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138
This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 19, 2019 at. 08:00 CET.
CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 45 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected].